The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases

Journal of Autoimmunity

Volumn 30, Issue 1-2, 2008, Pages 90-98

  Boren, Eric J ^a   Cheema, Gurtej S ^a   Naguwa, Stanley M ^a   Ansari, Aftab A ^b   Gershwin, M Eric ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

JC virus; Multiple sclerosis; Natalizumab (Tysabri); Progressive multifocal leukoencephalopathy; Rheumatic disease; Rituximab (Rituxan); Systemic lupus erythematosus

Indexed keywords

ALPHA2B INTERFERON; ANTIRETROVIRUS AGENT; CAMPTOTHECIN; CIDOFOVIR; CORTICOSTEROID; CYTARABINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; NATALIZUMAB; RITUXIMAB; SEROTONIN 2A ANTAGONIST; TOPOTECAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG APPROVAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; INFECTION; JC VIRUS; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATIC DISEASE; WEGENER GRANULOMATOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBODIES, MONOCLONAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HUMANS; IMMUNOCOMPROMISED HOST; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE IMAGING; RHEUMATIC DISEASES;

EID: 38049000341     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2007.11.013     Document Type: Review

References (105)

1. Calabrese L.H., Molloy E.S., Huang D.R., and Ransohoff R.M. Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56 7 (2007) 2116-2128
2. Koralnik I.J. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?. Ann Neurol 60 2 (2006) 162-173
3. Astrom K.E., Mancall E.L., and Richardson E.P. Progressive multifocal leukoencephalopathy. Brain 81 (1958) 93-127
4. Cavanaugh J.B., Greenbaum D., Marshall A., and Rubinstein L. Cerebral demyelination associated with disorders of the reticuloendothelial system. Lancet (1959) 524-529
5. Zu Rhein G.M., and Chou S.-M. Particles resembling papova viruses in human cerebral demyelinating disease. Science 148 (1965) 1477-1479
6. Padgett B.L., Walker D.L., ZuRhein G.M., et al. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1 (1971) 1257-1260
7. Frisque R.J., Bream G.L., and Cannella M.T. Human polyomavirus JC virus genome. J Virol 51 (1984) 458-469
8. Weber T., Trebst C., Frye S., et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176 (1997) 250-254
9. Stolt A., Sasnauskas K., Koskela P., et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 84 (2003) 1499-1504
10. Kitamura T., Aso Y., Kuniyoshi N., et al. High incidence of urinary JC virus excretion in nonimmunosuppressed older patients. J Infect Dis 161 (1990) 1128-1133
11. Koralnik I.J., Boden D., Mai V.X., et al. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52 (1999) 253-260
12. Monaco M.C., Jensen P.N., Hou J., et al. Detection of JC virus DNA in human tonsil tissue: evidence for site for initial viral infection. J Virol 72 (1998) 9918-9923
13. Elphick G.F., Querbes W., Jordan J.A., Gee G.V., Eash S., Manley K., et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306 (2004) 1380-1383
14. Atwood W.J., Amemiya K., Traub R., et al. Interaction of the human polyomavirus, JCV, with human B lymphocytes. Virology 190 (1992) 716-723
15. Monaco M.C., Atwood W.J., Gravell M., et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 70 (1996) 7004-7012
16. Dubois V., Dutrone H., Lafon M.E., et al. Latency and reactivation of JC virus in peripheral blood of human immunodeficiency virus type 1-infected patients. J Clin Microbiol 35 (1997) 2288-2292
17. Koralnik I.J., Schmitz J.E., Lifton M.A., et al. Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals. J Neurovirol 5 (1999) 430-435
18. Du Pasquier R.A., Autissier P., Zheng Y., Jean-Jacques J., and Koralnik I.J. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 19 (2005) 2069-2076
19. Sabath B.F., and Major E.O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 186 Suppl 2 (2002) S180-S186
20. Sweet T.M., Del Valle L., and Khalili K. Molecular biology and immunoregulation of human neurotropic JC virus in CNS. J Cell Physiol 191 (2002) 249-256
21. Hou J., Seth P., and Major E.O. JC virus can infect human immune and nervous system progenitor cells: implications for pathogenesis. Adv Exp Med Biol 577 (2006) 266-273
22. Aksamit A.J. Review of multifocal leukoencephaolpathy and natalizumab. Neurologist 12 6 (2006) 293-298
23. Lima M.A., Drislane F.W., and Koralnik I.J. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66 (2006) 262-264
24. Goetz C.G. DNA viruses. In: Goetz C.G. (Ed). Textbook of clinical neurology. 2nd ed. (2003), Saunders, Philadelphia chapter 41
25. von Einsiedel R.W., Fife T.D., Aksamit A.J., and Cornford M.E. Progressive multifocal leukoencephalopathy in AIDS: a clinicopathologic study and review of the literature. J Neurol 240 (1993) 391-406
26. Fong I.W., Britton C.B., Luinstra K.E., et al. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol 33 (1995) 484-486
27. Martinez J.V., Mazziotti J.V., Efron E.D., Bonardo P., Jordan R., et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67 (2006) 1692-1694
28. Brooks B.R., and Walker D.L. Progressive multifocal leukoencephalopathy. Neurol Clin 2 (1984) 299-313
29. Koralnik I.J., Schellingerhout D., and Frosch M.P. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14 - 2004. A 66 year-old man with progressive neurologic deficits. N Engl J Med 350 (2004) 1882-1893
30. Berger J.R. Natalizumab and progressive multifocal leukoencephalopathy. Ann Rheum Dis 65 Suppl. III (2006) iii48-iii53
31. Hall C.D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338 (1998) 1345-1351
32. Marra C.M., Rajicic N., Barker D.E., et al. A pilot study of cidofivir for progressive multifocal leukoencephalopathy in AIDS. Aids 16 (2002) 1791-1797
33. Royal III W., Dupont B., McGuire D., et al. Topotecan in the treatment in acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 9 (2003) 411-419
34. Geschwind M.D., Skolasky R.J., Royal W.S., and McArthur C. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 7 (2001) 353-357
35. O'Reilly S. Efficacy of camptothecin in progressive multifocal leukoencephalopathy. Lancet 350 (1997) 291
36. Kunschner L., and Scott T.F. Sustained recovery of multifocal leukoencephalopathy after treatment with IL-2. Neurology 65 (2005) 1510
37. Elphick G.F., Querbes W., Jordan J.A., et al. The human polyoma virus, JCV, uses serotonin receptors to infect cells. Science 306 (2004) 1380-1383
38. US Food and Drug Administration. FDA alert: natalizumab (Tysabri), http://www.fda.gov/cder/drug/Infopage/natalizumab/default.htm; May 22, 2006.
39. Berger J.R., and Koralnik U. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 353 (2005) 362-368
40. Ransohoff R.M. Natalizumab and PML. Nat Neurosci 8 (2005) 1275
41. Stuve O., Marra C.M., Jerome K.R., Cook L., Cravens P.D., Cepok S., et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 59 5 (2006) 731-737
42. Garcia-Suarez J., de Miguel D., Krsnik I., Banas H., Arribas I., and Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80 (2005) 271-281
43. Sponzilli E.E., Smith J.K., Malamud N., and McCulloch J.R. Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment. Neurology 25 7 (1975) 664-668
44. Rankin E., and Scaravilli F. Progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis and polymyositis. J Rheumatol 22 4 (1995) 777-779
45. Morgenstern L.B., and Pardo C.A. Progressive multifocal leukoencephalopathy complicating treatment for Wegener's granulomatosis. J Rheumatol 22 8 (1995) 1593-1595
46. Pagnoux C., Hayem G., Roux F., Rouidi S.A., Palazzo E., Henin D., et al. JC virus leukoencephalopathy complicating Wegener's granulomatosis. Joint Bone Spine 70 (2003) 376-379
47. Choy D.S., Weiss A., and Lin P.T. Progressive multifocal leukoencephalopathy following treatment for Wegener's granulomatosis. JAMA 268 5 (1992) 600-601
48. Wang H.-Y. Pathologic quiz case: a 54 year-old deceased man with diffuse subcortical lesions of the central nervous system. Arch Pathol Lab Med 128 (2004) e70-e72
49. Ettinger J., Feiden W., Hubner G., and Schreiner M. [Progressive multifocal leukoencephalopathy in Wegener's granulomatosis in relation to therapy with cyclosporine A]. Klin Wochenschr 67 4 (1989) 260-264 15
50. Cuevas L.A., and Fuchs H.A. Progressive multifocal leukoencephalopathy and imunosuppression (letter). Ann Rheum Dis 63 (2004) 112-113
51. Gentile S., Sacerdote I., Roccatello D., and Giordana M.T. Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report. Ital J Neurol Sci 17 5 (1996) 363-366
52. Tubridy N., Wells C., Lewis D., and Schon F. Unsuccessful treatment with cidofivir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis. J R Soc Med 93 (2000) 374-375
53. Vulliemoz S., Lurati-Ruiz F., Borruat F.X., Delavelle J., Koralnik I.J., Kuntzer T., et al. Favourable outcome of progressive multifocal leukoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 77 (2006) 1079-1082
54. Richardson Jr. E.P., and Johnson P.C. Atypical progressive multifocal leukoencephalopathy with plasma-cell infiltrates. Acta Neuropathol Suppl (Berl) Suppl. 6 (1975) 247-250
55. Hahn J.S., Harris B.T., Gutierrez K., and Sandborg C. Progressive multifocal leukoencephalopathy in a 15-year-old boy with scleroderma and secondary amyloidosis. Pediatrics 102 (1998) 1475-1479
56. Warnatz K., Peter H.H., Schumacher M., Wiese L., Prasse A., Petschner F., et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 62 (2003) 50-57
57. Govindappa V., Hicks S., Wichter M., and Jolly M. Progressive Multifocal Leukoencephalopathy in Systemic Lupus Erythematosus. Arthritis Rheum 52 2 (2007) 352-354
58. Henderson R.D., Smith M.G., Mowat P., and Read S.J. Progressive multifocal leukoencephalopathy. Neurology 58 12 (2002) 1825
59. Jones Jr. H.R., Hedley-Whyte E.T., Freidberg S.R., Kelleher Jr. J.E., and Krolikowski J. Primary cerebellopontine progressive multifocal leukoencephalopathy diagnosed premortem by cerebellar biopsy. Ann Neurol 11 (1982) 199-202
60. Krupp L.B., Lipton R.B., Swerdlow M.L., Leeds N.E., and Llena J. Progressive multifocal leukoencephalopathy: clinical and radiographic features. Ann Neurol 17 4 (1985) 344-349
61. Tomura N., Watanabe M., Kato T., Nishino K., and Kowada M. Case report: Progressive multifocal leukoencephalopathy with prominent medullary veins on angiogram. Clin Radiol 49 (1994) 66-68
62. Ahmed F., Aziz T., and Kaufman L.D. Progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosis. J Rheumatol 26 7 (1999) 1609-1612
63. Malas D., and Weiss S. Progressive multifocal leukoencephalopathy and cryptococcal meningitis with systemic lupus erythematosus and thymoma. Ann Neurol 1 (1977) 188-191
64. Salmaggi A., Maccagnano E., Castagna A., Zeni S., Fantini F., Cinque P., et al. Reversal of CSF positivity for JC virus genome by cidofivir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurol Sci 22 1 (2001) 17-20
65. Itoh K., Kano T., Nagashio C., Mimori A., Kinoshita M., and Sumiya M. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 54 3 (2006) 1020-1025
66. Arbusow V., Strupp M., Pfister H.W., Seelos K.C., Bruckmann H., and Brandt T. Contrast enhancement in progressive multifocal leukoencephalopathy: a predictive factor for long-term survival?. J Neurol 247 (2000) 306-308
67. Reilmann R., Imai T., Ringelstein E.B., Gaubitz M., Niederstadt T.U., Paulus W., and Husstedt I.W. Remission of progressive multifocal leukoencephalopathy in SLE after treatment with cidofivir: a 4 year follow up. J Neurol Neurosurg Psychiatry 76 (2005) 1304-1305
68. Newton P., Aldridge R.D., Lessells A.M., and Best P.V. Progressive multifocal leukoencephalopathy complicating systemic lupus erythematosus. Arthritis Rheum 29 3 (1986) 337-343
69. Weiner L.P., Herndon R.M., Narayan O., Johnson R.T., Shah K., Rubinstein L.J., et al. Isolation of virus related to SV40 from patients with progressive multifocal leukoencephalopathy. N Engl J Med 286 8 (1972) 385-390
70. Vandecasteele S.J., Maes B., Claes K., Sciot R., and Vanrenterghem Y. High anti-double-stranded DNA antibodies and progressive multifocal leukoencephalopathy in a patient with systemic lupus erythematosus. Nephrol Dial Transplant 20 (2005) 1246-1247
71. Slooff J.L. Two cases of progressive multifocal leuko-encephalopathy with unusual aspects. Psychiatr Neurol Neurochir 69 (1966) 461-474
72. Vollmer-Haase J., Young P., and Ringelstein E.B. Efficacy of camptothecin in progressive multifocal leukoencephalopathy. Lancet 349 (1997) 66
73. White R.P., Abraham S., Singhal S., Manji H., and Clarke C.R.A. Progressive multifocal leukoencephalopathy isolated to the posterior fossa in a patient with systemic lupus erythematosus. Rheumatology 41 (2002) 826-836
74. Hseuh C., and Reyes C.V. Progressive multifocal leukoencephalopathy. Am Fam Physician 37 6 (1988) 129-132
75. Kinoshita M., Iwana K., Shinoura H., Aotsuka S., and Sumiya M. Progressive multifocal leukoencephalopathy resembling central nervous system systemic lupus erythematosus. Clin Exp Rheumatol 16 3 (1998) 313-315
76. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 20 - 1995. A 66-year-old man with a history of rheumatoid arthritis treated with adrenocorticosteroids, with the development of aphasia and right-sided weakness. N Engl J Med 332 (1995) 1773-1780
77. Arbusow V., Strupp M., Samtleben W., Hatz H., Bruckmann H., and Brandt T. [Progressive multifocal leukoencephalopathy as a result of immunosuppressive therapy]. Dtsch Med Wochenschr 124 21 (1999) 653-656
78. Midorikawa T., Totsuka S., and Hotta T. [Progressive multifocal leukoencephalopathy confirmed at autopsy in a case of systemic lupus erythematosus with marked psychiatric symptoms]. Rinsho Shinkeigaku 14 10 (1974) 799-805
79. Blank M., and Shoenfeld Y. B cell targeted therapy in autoimmunity. J Autoimmun 28 (2007) 62-68
80. Alvarado-Sanchez B., Hernandez-Castro B., Portales-Perez D., Baranda L., Layseca-Espinosa E., et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 27 (2006) 110-118
81. Gaipl U.S., Munoz L.E., Grossmayer G., Lauber K., Franz S., et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 28 (2007) 114-121
82. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., and Routsias J.G. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 26 (2006) 165-171
83. Youinou P. B cell conducts the lymphocyte orchestra. J Autoimmun 28 (2007) 143-151
84. Edwards J.C., and Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6 (2006) 394-403
85. US Food and Drug Administration. FDA Alert: rituximab (marketed as Rituxan), http://www.fda.gov/cder/drug/Infopage/rituximab/default.htm; Dec 2006.
86. Saketkoo L.A., and Espinoza L.R. Impact of biologic agents on infectious diseases. Infect Dis Clin N Am 20 (2006) 931-961
87. Abraham M, et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun (in press).
88. Andreoli L, et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity. J Autoimmun (in press).
89. Avrameas S., et al. Naturally occurring B-cell autoreactivity: a critical overview. J Autoimmun 29 (2007) 213-218
90. Binard A, et al. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus? J Autoimmun (in press).
91. Cohen I.R. Biomarkers, self-antigens and the immunological homunculus. J Autoimmun 29 (2007) 246-249
92. Gebe JA, et al. Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. J Autoimmun (in press).
93. Jacobson E, Huber A, Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun (in press).
94. Kallenberg C. Pathogenesis of PR3-ANCA associated vasculitis. J Autoimmun (in press).
95. Lan R.Y., Mackay I.R., and Gershwin M.E. Regulatory T cells in the prevention of mucosal inflammatory diseases: patrolling the border. J Autoimmun 29 (2007) 272-280
96. Lang K.S., et al. The role of the innate immune response in autoimmune disease. J Autoimmun 29 (2007) 206-212
97. Leskovek N, Mackay I, Rose NCell damage and autoimmunity: a critical appraisal. J Autoimmun (in press).
98. Lutz H.U. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 29 (2007) 287-294
99. Milner J., et al. Repertoire-dependent immunopathology. J Autoimmun 29 (2007) 257-261
100. Nakanishi Y, et al. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J Autoimmun (in press).
101. Papadimitraki E.D., Bertsias G.K., and Boumpas D.T. Toll like receptors and autoimmunity: a critical appraisal. J Autoimmun 29 (2007) 310-318
102. Pasquali J.L., et al. Auto-reactive B cells in transgenic mice. J Autoimmun 29 (2007) 250-256
103. Peng Y., et al. Innate and adaptive immune response to apoptotic cells. J Autoimmun 29 (2007) 303-309
104. Poletaev A, Stepanyuk V, Gershwin M. Integrating immunity: the immunculus and self reactivity. J Autoimmun (in press).
105. Praprotnik S, et al. The curiously suspicious: infectious disease may ameliorate an ongoing autoimmune destruction in systemic lupus erythematosus patients. J Autoimmun (in press).